Floatz logo

Alpha-Interferon

Cervix Neoplasms

The University of Texas Health Science Center, HoustonPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

160 Active assets in the Cervix Neoplasms cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
Indocyanine Green
Istanbul University
Phase 4BB
Carboplatin
Merck Sharp & Dohme LLC
Phase 3B
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

Alpha-Interferon is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
74 / 100
View asset →
renal cell carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
kidney cancerDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →